Krystal Biotech Stock Analysis

KRYS Stock  USD 182.29  4.19  2.35%   
Krystal Biotech is overvalued with Real Value of 144.49 and Target Price of 150.44. The main objective of Krystal Biotech stock analysis is to determine its intrinsic value, which is an estimate of what Krystal Biotech is worth, separate from its market price. There are two main types of Krystal Biotech's stock analysis: fundamental analysis and technical analysis.
The Krystal Biotech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Krystal Biotech is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Krystal Stock trading window is adjusted to America/New York timezone.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krystal Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Krystal Stock Analysis Notes

About 12.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania. Krystal Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. To find out more about Krystal Biotech contact the company at 412 586 5830 or learn more at https://www.krystalbio.com.

Krystal Biotech Investment Alerts

Krystal Biotech generated a negative expected return over the last 90 days
Krystal Biotech currently holds about 425.56 M in cash with (88.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 16.58.
Krystal Biotech has a poor financial position based on the latest SEC disclosures
Over 88.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Segall Bryant Hamill LLC Boosts Stock Position in Krystal Biotech, Inc. - MarketBeat

Krystal Biotech Upcoming and Recent Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Krystal Largest EPS Surprises

Earnings surprises can significantly impact Krystal Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2018-03-12
2017-12-31-0.23-0.26-0.0313 
2019-05-06
2019-03-31-0.33-0.290.0412 
2019-03-12
2018-12-31-0.23-0.27-0.0417 
View All Earnings Estimates

Krystal Biotech Environmental, Social, and Governance (ESG) Scores

Krystal Biotech's ESG score is a quantitative measure that evaluates Krystal Biotech's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Krystal Biotech's operations that may have significant financial implications and affect Krystal Biotech's stock price as well as guide investors towards more socially responsible investments.

Krystal Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Hood River Capital Management Llc2024-09-30
502.1 K
Goldman Sachs Group Inc2024-06-30
422.3 K
Jennison Associates Llc2024-09-30
410.1 K
Lord, Abbett & Co Llc2024-06-30
392.2 K
Nuveen Asset Management, Llc2024-06-30
336.2 K
Woodline Partners Lp2024-06-30
291.9 K
Amvescap Plc.2024-06-30
275.1 K
Charles Schwab Investment Management Inc2024-09-30
240.2 K
Northern Trust Corp2024-09-30
238.7 K
Fmr Inc2024-09-30
4.3 M
Blackrock Inc2024-06-30
3.9 M
Note, although Krystal Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Krystal Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.12 B.

Krystal Profitablity

The company has Profit Margin (PM) of 0.22 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.42 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.42.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.01  0.01 
Return On Capital Employed(0.14)(0.15)
Return On Assets 0.01  0.01 
Return On Equity 0.01  0.01 

Management Efficiency

Krystal Biotech has return on total asset (ROA) of 0.0458 % which means that it generated a profit of $0.0458 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0638 %, meaning that it created $0.0638 on every $100 dollars invested by stockholders. Krystal Biotech's management efficiency ratios could be used to measure how well Krystal Biotech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Krystal Biotech's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.15) in 2024. At this time, Krystal Biotech's Total Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 630.6 M in 2024, whereas Other Current Assets are likely to drop slightly above 4.2 M in 2024.
Last ReportedProjected for Next Year
Book Value Per Share 28.67  30.11 
Tangible Book Value Per Share 28.67  30.11 
Enterprise Value Over EBITDA 168.59  177.02 
Price Book Value Ratio 4.33  4.11 
Enterprise Value Multiple 168.59  177.02 
Price Fair Value 4.33  4.11 
Enterprise ValueB3.2 B
The strategic vision of Krystal Biotech management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Operating Margin
0.4167
Profit Margin
0.2168
Beta
0.82
Return On Assets
0.0458
Return On Equity
0.0638

Technical Drivers

As of the 22nd of November, Krystal Biotech secures the Standard Deviation of 2.41, mean deviation of 1.75, and Risk Adjusted Performance of (0.04). Krystal Biotech technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Krystal Biotech risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Krystal Biotech is priced some-what accurately, providing market reflects its recent price of 182.29 per share. Given that Krystal Biotech has information ratio of (0.1), we recommend you to check Krystal Biotech's last-minute market performance to make sure the company can sustain itself at a future point.

Krystal Biotech Price Movement Analysis

Execute Study
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Krystal Biotech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Krystal Biotech. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Krystal Biotech Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Krystal Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Krystal Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Krystal Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Suma Krishnan over two months ago
Disposition of 5109 shares by Suma Krishnan of Krystal Biotech at 170.3241 subject to Rule 16b-3
 
Suma Krishnan over three months ago
Disposition of 2816 shares by Suma Krishnan of Krystal Biotech at 172.0593 subject to Rule 16b-3
 
Krishnan Krish S over three months ago
Disposition of 5705 shares by Krishnan Krish S of Krystal Biotech at 176.6786 subject to Rule 16b-3
 
Rossi Dino A over three months ago
Acquisition by Rossi Dino A of 5000 shares of Krystal Biotech at 183.64 subject to Rule 16b-3
 
Krishnan Krish S over three months ago
Disposition of 1871 shares by Krishnan Krish S of Krystal Biotech at 178.1447 subject to Rule 16b-3
 
Gangolli Julian S over six months ago
Disposition of 20000 shares by Gangolli Julian S of Krystal Biotech at 22.75 subject to Rule 16b-3
 
Gangolli Julian S over six months ago
Disposition of 20000 shares by Gangolli Julian S of Krystal Biotech at 22.75 subject to Rule 16b-3
 
Suma Krishnan over six months ago
Disposition of 7500 shares by Suma Krishnan of Krystal Biotech subject to Rule 16b-3
 
Suma Krishnan over six months ago
Disposition of 800 shares by Suma Krishnan of Krystal Biotech at 174.1313 subject to Rule 16b-3
 
Krishnan Krish S over six months ago
Acquisition by Krishnan Krish S of 12500 shares of Krystal Biotech subject to Rule 16b-3
 
Krishnan Krish S over six months ago
Disposition of 800 shares by Krishnan Krish S of Krystal Biotech at 174.1313 subject to Rule 16b-3
 
Kathryn Romano over six months ago
Exercise or conversion by Kathryn Romano of 2500 shares of Krystal Biotech subject to Rule 16b-3

Krystal Biotech Outstanding Bonds

Krystal Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Krystal Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Krystal bonds can be classified according to their maturity, which is the date when Krystal Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Krystal Biotech Predictive Daily Indicators

Krystal Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Krystal Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Krystal Biotech Corporate Filings

13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
13A
12th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
8K
4th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
16th of October 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934
ViewVerify
F4
13th of September 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
28th of August 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
5th of August 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
13A
10th of July 2024
An amended filing to the original Schedule 13G
ViewVerify

Krystal Biotech Forecast Models

Krystal Biotech's time-series forecasting models are one of many Krystal Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Krystal Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Krystal Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Krystal Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Krystal shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Krystal Biotech. By using and applying Krystal Stock analysis, traders can create a robust methodology for identifying Krystal entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin 0.23  0.24 
Operating Profit Margin(1.95)(2.05)
Net Profit Margin 0.19  0.20 
Gross Profit Margin 0.85  0.72 

Current Krystal Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Krystal analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Krystal analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
150.44Strong Buy11Odds
Krystal Biotech current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Krystal analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Krystal stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Krystal Biotech, talking to its executives and customers, or listening to Krystal conference calls.
Krystal Analyst Advice Details

Krystal Stock Analysis Indicators

Krystal Biotech stock analysis indicators help investors evaluate how Krystal Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Krystal Biotech shares will generate the highest return on investment. By understating and applying Krystal Biotech stock analysis, traders can identify Krystal Biotech position entry and exit signals to maximize returns.
Begin Period Cash Flow161.9 M
Common Stock Shares Outstanding27.8 M
Total Stockholder Equity778.6 M
Tax ProvisionM
Quarterly Earnings Growth Y O Y-0.674
Property Plant And Equipment Net168.2 M
Cash And Short Term Investments532.2 M
Cash358.3 M
Accounts Payable1.8 M
Net Debt-350.2 M
50 Day M A180.448
Total Current Liabilities33.1 M
Other Operating Expenses160.4 M
Non Current Assets Total230.4 M
Forward Price Earnings31.9489
Non Currrent Assets Other263 K
Stock Based Compensation39.9 M

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.